Rapafusyn Pharmaceuticals to Present at the H.C. Wainwright 28th Annual Global Investment Conference
BALTIMORE, Sept. 2, 2026 /PRNewswire/ — Rapafusyn Pharmaceuticals, a leader in the discovery and development of non-degrading molecular glue therapeutics, today announced that Dr. Sean Hu, President and Chief Executive Officer of Rapafusyn Pharmaceuticals, will present a company overview at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-15, 2026, in New York, NY.
The presentation will be available beginning Friday, September 11, 2026, at 7:00 a.m. ET. It can be accessed on the News section of the Company’s website at www.rapafusyn.com,
About Rapafusyn Pharmaceuticals
Rapafusyn emerged from the laboratory of Dr. Jun O. Liu’s, Professor of Pharmacology and Molecular Sciences at Johns Hopkins University, with a mission to develop transformational medicines to address high unmet medical needs and enhance patient care. The platform leverages highly selective non-degrading macrocyclic molecular glue inhibitors (RapaGluesâ„¢) to address challenging therapeutic targets, and has proven effective in discovering novel molecular glue inhibitors on a regular basis. Rapafusyn has constructed both DNA-encoded libraries (DELs) and arrayed libraries of RapaGluesâ„¢ that form neo-PPIs to inhibit a disease protein from its native activity. These compounds are rationally designed and engineered to bind FKBP and form a ternary complex with the disease target protein, offering a promising avenue for modulating intricate protein-protein interactions, transcription factors, transmembrane receptors, transporters/SLCs, enzymes and ligases. RapaGluesâ„¢ have produced innovative drug candidates for broad types of challenging drug targets, and frequently exhibit cell permeability directly from the starting point, enhancing their potential for therapeutic development. The modular architecture enables SAR and subsequent optimization for potency, selectivity, and physicochemical properties to accelerate drug discovery and development.
For more information, please visit www.rapafusyn.com.
Company Contact
[email protected]
Investors & Media
Argot Partners
[email protected]Â

View original content to download multimedia:https://www.prnewswire.com/news-releases/rapafusyn-pharmaceuticals-to-present-at-the-hc-wainwright-28th-annual-global-investment-conference-302866778.html
SOURCE Rapafusyn Pharmaceuticals

More from Cision PR Newswire
See all
Legacy Healthcare Welcomes U.S. Congressional Legislation Proposing 12-Year Market Exclusivity for US FDA Newly Approved Botanical Drugs

Triskell Software Positioned for the First Time in the 2026 Gartner® Magic Quadrant™ for Adaptive Project Management and Reporting

RAMINVEST HOLDING DIFC Unveils an Integrated Ecosystem for Commodity Trade with Africa

Qapture Investments Establishes Investment Manager and Acquires Hermetik Trading’s DeFi Strategies; Appoints Brendan MacNeil as Head of DeFi
Recommended for you
More stories
Future of AICysic CEO Says Paying for an AI Model Doesn’t Prove Your Host Ran It
AI & TechnologyFrom self-driving excavators to AI leasing agents, proptech’s AI moment has arrived
AI & TechnologyAI literacy shouldn’t begin in the workplace. It should begin in primary school.
DataThe Data Centre Is Becoming a Product
AI & TechnologyToo often, AI narrows rather than widens access. Here’s how the tech industry can fix it
AI & Technology